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ABSTRACT 
Microcin J25 (MccJ25) is a plasmid-encoded, ribosomally synthesized antibacterial peptide with 
a unique lasso structure.  The lasso structure, produced with the aid of two processing enzymes, 
provides exceptional stability to MccJ25.  We report the synthesis of six peptides (1-6), derived 
from the MccJ25 sequence, that are designed to form folded conformation by disulfide bond 
formation and electrostatic or hydrophobic interactions.  Two peptides (1 and 6) display good 
activity against Salmonella newport, and are the first synthetic derivatives of MccJ25 that are 
bactericidal.  Peptide 1 displays potent activity against several Salmonella strains including two 
MccJ25 resistant strains.  The solution conformation and the stability studies of the active 
peptides suggest that they do not fold into a lasso conformation and peptide 1 displays 
antimicrobial activity by inhibition of target cell respiration.  Like MccJ25, the synthetic MccJ25 
derivatives display minimal toxicity to mammalian cells suggesting that these peptides act 
specifically on bacterial cells. 
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1. Introduction 
Microcin J25 (MccJ25) is a 21-residue ribosomally synthesized antimicrobial peptide that 
adopts a remarkable threaded-lasso structure.1-3  MccJ25 displays bactericidal activity against a 
range of food-borne disease-causing Gram-negative pathogens including diarrheagenic E. coli 
strains.4  The lasso-structure of the peptide consists of a lactam ring (known as lariat ring) 
formed between the N-terminus Gly1 and the side chain of Glu8 (Figure 1).5-7  The C-terminal 
tail (Tyr9-Gly21) passes through the ring forming a β-hairpin structure made of a type I β-turn 
(Val11-Gly14) and two short double stranded antiparallel β-sheets, residues 6-7/19-20 and 10-
11/15-16.   
The active mature MccJ25 is produced and exported by four plasmid-encoded genes 
mcjABCD.8  McjA encodes a linear 58-residue precursor peptide which is converted into mature 
peptide by two enzymes, McjB and McjC.9, 10  McjB, a putative peptidase, cleaves the 37-residue 
leader peptide from the precursor peptide, whereas, McjC is believed to catalyze the lactam bond 
formation. McjD helps in the transport of the active antibiotic peptide out of the producing cell.11  
The lasso-structure confers several properties to MccJ25, such as, resistance to proteolytic 
degradation,12, 13 stability towards chaotropes, organic solvents, and extreme temperatures.14  
Such properties make MccJ25 a potential candidate for a number of applications including food 
preservation and treatment of food-borne diseases. 
Different variants of MccJ25, prepared by site directed mutagenesis, have been reported 
for studying structure activity relationship (SAR).15, 16  Pavlova et al. performed a complete 
mutational scanning analysis of MccJ25 by making more than 380 MccJ25 variants with a single 
amino acid substitution.16  Each single amino acid variant was tested for production and export 
from E.coli.  In addition, the variants that were produced were analyzed for the ability to inhibit 
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RNA polymerase (RNAP) and bacterial growth.  Several residues in the lactam ring and the tail 
region were found to be important for the production of MccJ25 and inhibition of bacterial 
growth.  Another study reported MccJ25 variants containing two or three amino acid 
substitutions where the peptides retain the lasso structure and the antimicrobial function.15  These 
studies demonstrate that peptide lasso scaffold of MccJ25 is quite tolerant to amino acid 
substitutions.  Additional SAR studies of MccJ25 have suggested that the lactam ring region and 
the tail β-hairpin loop play distinct roles in the peptide’s antimicrobial activity.17, 18  In particular, 
using a thermolysin-digested MccJ25 cleaved between residues 10 and 11 it was demonstrated 
that the β-hairpin (residues 10-16) is crucial in the import of MccJ25 through FhuA, but not for 
RNAP and respiration inhibition.18  The roles played by specific residues in the peptide have also 
been reported.19, 20  The C-terminal glycine was found to be important for RNAP inhibition,19 
while site specific mutation of His-5 demonstrated that this residue was important for recognition 
by the inner membrane receptor SbmA.20 
Attempts have also been made to chemically synthesize MccJ25 variants, such as, 
macrocyclic head-to-tail 21-residue MccJ25, a 21-residue variant with side chain-to-backbone 
lactam ring between -amino of Gly1 and -carboxyl of Glu8, and a recently reported MccJ25 
model peptide (cMccJ25) where Gly1 and Glu8 are replaced with nearly isosteric azidoacetic acid 
and propargyl glycine, respectively.5, 6, 21  In the later variant (cMccJ25), the copper-catalyzed 
click reaction between the azide and the terminal alkyne permits cyclization of cMccJ25 without 
the influence of the maturation enzymes.21  None of these synthetic peptides showed any 
antibacterial activity. 
We hypothesized that peptides with antibacterial activity can be designed based on the 
MccJ25 sequence where a folded conformation is acquired by a combination of intra-peptide 
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disulfide bond formation and electrostatic or hydrophobic interactions, instead of post-
translational modification by McjB and McjC proteins.  To test our hypothesis, six peptides (1-6) 
derived from the sequence of MccJ25 ranging in length 18-22 residues were designed and 
synthesized (Figure 1).  We report herein the results of antimicrobial activity, solution 
conformation, stability to proteases and cytotoxicity of this series of synthetic MccJ25 
derivatives. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  (A) A 58 amino acid McjA precursor peptide is converted into mature antimicrobial 
form, MccJ25 by McjB and McjC enzymes.  The ribbon representation of the lasso structure of 
MccJ25 (PDB ID code 1Q71)6 is shown.  Antiparallel β-sheets are shown in green and yellow, 
and the amide bond between residues G1-E8 is shown as stick model. (B) Amino acid sequences 
of MccJ25 and derived peptides 1-6.  Substitutions of amino acids in the peptide derivatives are 
shown in yellow for cysteine and red for others. 
6 
 
 
2. Results and Discussion 
Six peptides were designed on the basis of the MccJ25 sequence following the strategy 
that intra-peptide interactions will lead to active peptide derivatives.  Peptides were designed to 
form folded conformation by intra-peptide (i) disulfide and amide bond formation (analogues 1 
and 2), (ii) disulfide and electrostatic interactions (3 and 4), or (iii) disulfide and hydrophobic 
interactions (5 and 6).  In peptide 1, the lactam ring of MccJ25 between G1 and E8 was 
maintained, and a disulfide bond between C4 and C20 (C-terminal) was introduced to hold the 
C-terminal of the peptide in place.  In all other peptides (2-6), the isopeptide bond between G1 
and E8 was replaced with a disulfide bond.  Peptide 2, an 18-residue peptide, utilized an amide 
bond to tie the N-terminal C1 with the C-terminal E18.  Peptides 3 and 4 contain substitution of a 
ring residue and one residue from the tail region with positively and negatively charged amino 
acids, respectively, for electrostatic interactions (H5K, Y20E in 3 and G4K, Y20E in 4).  
Similarly, peptides 5 and 6 contain substitution or insertion with hydrophobic amino acids, such 
as G4F in 5.  Peptide 6 consists of a larger 9-residue N-terminal ring, as expansion of the ring 
was thought to facilitate the insertion of the C-terminal into the N-terminal lariat ring by 
interaction between F5 and F19 and/or Y20.  An aromatic hydrophobic Phe (F) residue was 
inserted between G4 and H5 for enhanced van der Waals and stacking interactions with the C-
terminal F19 and Y20.  In addition, I13R and/or T15G substitutions (replacement of hydrophobic 
Ile with basic guanidine containing Arg and Thr with a methyl side chain with Gly with no side 
chain) were introduced in peptides 2, 5, and 6 to increase solubility.  These mutations have been 
reported to yield higher inhibitory activity compared to the wild-type MccJ25.16 
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Peptides 1-6 were synthesized as linear peptides using Fmoc solid-phase peptide 
synthesis.  For peptides 1 and 2, the lactam bond formation was achieved on the solid-phase, 
followed by cleavage from the resin.  The second ring (disulfide bond) was then formed in 
solution.  Peptides 3-6 were cleaved from the resin as linear peptides followed by oxidation to 
form disulfide bond.  The electrostatic or hydrophobic interactions in the peptides were initiated 
when the peptides were cleaved from the solid phase and the side chain protections were 
removed.  Native MccJ25 was expressed using pTUC202 plasmid in E. coli MC4100 in M9 
minimal media.12 Crude peptides were purified using semi-preparative reversed-phase HPLC 
prior to characterization by electrospray and/or MALDI-TOF mass spectrometry (Table S1, 
supplementary data).  All peptides were purified up to >95% purity as shown by analytical RP-
HPLC and mass spectrometry (Figures S1 and S2), and were obtained with an overall yield of 7-
32%. 
The antibacterial activity of MccJ25 and peptides 1-6 was evaluated against a number of 
Gram-negative pathogens.  Twelve Salmonella strains and two E. coli strains were used to obtain 
the activity profile of the peptides using liquid growth inhibition assay (Table 1).22  Peptides 1 
and 6 displayed good activity (low micromolar range) against S. newport with MIC values of 25 
and 30 M, respectively (Figure 2).  Compared to the native MccJ25 (MIC 0.5 M), these 
peptides were 50-60 fold less potent.  Interestingly, 1 also displayed activity against several 
(five) other Salmonella strains including two MccJ25 resistant strains.  For all of these strains, 
MIC of 1 was in the range of 75-90 M.  The MIC of MccJ25 was also higher (compared to S. 
newport) for the three MccJ25 sensitive strains.  Peptides 1-6 were also tested for inhibition of 
Gram-positive bacteria, such as S. aureus ATCC 6538 and E. faecalis ATCC 19433.  These 
peptides showed no activity against Gram-positive strains. 
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A number of different MIC values of MccJ25, ranging from 5 nM to 0.22 M, against S. 
newport have been reported previously.3,12,23,24  In this study, we found the MIC value of MccJ25 
to be 0.5 M against a clinical isolate of S. newport.  This variation in MIC values could be due 
to the difference in the experimental conditions used, such as spot-on-lawn assay, liquid growth 
assay, media with or without supplements, or the difference in the strains used.   
 
Table 1.  Antibacterial activity of MccJ25 and synthetic peptide derivatives (1 and 6) against 
Gram-negative bacterial strains 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strainsa 
MICb (M) of Peptides 
MccJ25 1 6 
S. newport 0.5 ± 0.05 25 ± 3.0 30 ± 4.0 
S. enteritidis PT8 1.5 ± 0.8 80 ± 3.0 - 
S. enteritidis ATCC13076 1.8 ± 0.7 - - 
S. enteritidis AFLB 11 2.0 ± 0.6 - - 
S. enteritidis AFLB 41 1.6 ± 1.0 - - 
S. enteritidis AFLB 81 1.7 ± 1.2 - - 
S. typhimurium AFLB 25 2.8 ± 0.8 85 ± 5.2 - 
S. typhimurium ATCC 13311 - 75 ± 6.5 - 
S. heidelberg ATCC 8326 - 83 ± 6.1 - 
S. montevideo 20 - - - 
S. paratyphi 1.5 ± 1.0 - - 
S. choleresius ATCC 10708 1.5 ± 0.6 90 ± 5.7 - 
E. coli DH5α 5.0 ± 1.0 - - 
E. coli MC4100 5.0 ± 2.0 - - 
aDetails for the bacterial strains are provided in Table S2 (supplementary data).  
bMIC value is the last concentration of the peptide (M) giving 100% inhibition 
of the strain.  -, no activity detected up to 250 µM.  Data are represented as 
means ± standard errors of the means.  The values are results of at least three 
independent measurements.   
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Figure 2.  Growth curves of microcin J25, peptide 1, and peptide 6 using broth assay against 
Salmonella newport.  MICs were defined as the lowest peptide concentration that caused 100% 
growth inhibition (0.05 AU). 
 
Furthermore, peptides 1 and 6 were found to be bactericidal similar to MccJ25.4  The 
minimum bactericidal concentrations (MBCs) of peptides 1 and 6 against S. newport were 31.25 
and 62.5 M, respectively.  The MBCs of peptide 1 against S. enteritidis ATCC P76, S. 
typhimurium ATCC 13311, and S. choleresius ATCC 10708 were 125 M each.  A number of 
synthetic analogues of MccJ25 have been reported, however, none of them display activity 
against Gram-negative pathogens.6,7,13,21  To our knowledge, peptides 1 and 6 are the first 
synthetic derivatives of MccJ25 that display antibacterial activity.  Peptides 2-5 lacked 
antimicrobial activity against all of the tested strains up to 250 M concentration.  One striking 
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feature of peptides 2-5 was the replacement of lactam bond with a disulfide linkage.  Although 
the same is true for peptide 6, but the replacement was better tolerated due to the expanded 9-
residue lariat ring.  A variant of peptide 6 with 8-residue lactam ring 
(CGAFHVPCYFVGRGTPISFYG) was synthesized (not shown here) and was found to be 
inactive suggesting larger lactam ring facilitates interaction between the C-terminal tail and the 
N-terminal ring.  The reduced activity of 1 and 6 compared to the native MccJ25 could be due to 
the loss of characteristic lasso conformation.   
Circular dichroism (CD) spectroscopy was used to study the folding behavior of peptides 
1 and 6 in solution.  Methanol was used as a solvent for CD studies due to the limited solubility 
of the peptides in water.  Moreover, methanol has been used previously to elucidate the solution 
structure (NMR structure) of MccJ25.6  The CD spectra of peptides 1 and 6 in methanol were 
very different from MccJ25 suggesting different folded structures in solution (Figure 3).  The CD 
spectrum of MccJ25 in methanol displayed a minimum at 200 nm (= -3.2 x 103) and a 
maximum at 225 nm (= 1.1 x 103) with a positive shoulder at 215 nm (Figure 3) consistent 
with the previously reported spectrum.25  A negative peak at 200 nm is characteristic of 
unstructured peptides; however, this peak has also been attributed to small -sheets or β-turn 
secondary structures such as in β-defensins.26  The positive band at ca. 225 and 210 nm have 
been attributed to the Phe La and Tyr La transitions.
27  CD of peptide 1 showed a broad minimum 
at 208 nm with low intensity (= -1.5 x 103), whereas, peptide 6 displayed a minimum at 210 
nm (= -5.0 x 103) with a shoulder at 226 nm (= -1.8 x 103).  Quantitative analysis of the 
secondary structure of peptide 6 with CDPro28 suggested that there is little -sheet conformation 
(~ 15% residues form -sheet) compared to MccJ25 (39%).  Peptide 6 showed the presence of 
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increased helical folding.  These results suggest that both the active peptides (1 and 6) may adopt 
a constrained and compact folded structure, however, do not adopt the true lasso structure as 
observed in MccJ25. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Circular dichroism spectra for MccJ25, 1 and 6 in methanol at 25 ºC. 
 
 
Furthermore, the absence of lasso conformation in peptides 1 and 6 was confirmed by 
enzyme stability studies.  MccJ25 is known to be highly stable to degradation in the presence of 
proteolytic enzymes, such as chymotrypsin, trypsin, carboxypeptidase and pepsin.12  In contrast, 
both 1 and 6 were not stable in the presence of chymotrypsin and pepsin.  During the 
antimicrobial assay, the circular growth inhibition zones of 1 and 6 were distorted to a crescent-
shape in the presence of a drop of chymotrypsin.  Likewise, reversed-phase HPLC analysis of 
195 210 225 240
-6
-3
0
3
 
 

 x
 1
0
-3
 (
d
e
g
 c
m
2
 d
m
o
l-1
)
Wavelength (nm)
 MccJ25
 1
 6
12 
 
peptides 1 and 6 incubated with pepsin for 30 minutes showed complete degradation of the 
peptides (Figure 4).  For peptide 1, the presence of fragments FVGIGTPIS and FVGIGTPISF 
showed that the cleavage occurred before and after the C-terminal Phe residue (Phe19).  This 
suggests that the C-terminal cysteine is present outside the ring (N-terminal ring between Gly1 
and Glu8) allowing access to the C-terminal residues for cleavage by enzymes such as pepsin.  
Peptide 6 also gave similar degradation products after incubation with pepsin.  However, 
fragments from cleavage near Phe5 residue, which is present inside the N-terminal ring (between 
Cys1 and Cys9) of 6, were not detected.  Interestingly, the evaluation of thermostability of 1 and 
6 showed that only peptide 1 was active after incubation in boiling water for 3 hours.  This may 
be due to its rigid bicyclic ring structure allowing high heat resistance similar to wild-type 
MccJ25.  The disulfide bond was found to be intact for peptide 1 after boiling treatment.  
Peptides 1 and 6 with reduced cysteine residues (absence of disulfide bond) were found to 
display no antimicrobial activity. 
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Fragment # Sequence Mass Found 
Peptide 1   
1 FVGIGTPIS and FVGIGTPISF 889.1 and 1036.5 
2 GGACHVPEY-C and GGACHVPEY-FC 1034.6 and 1181.2 
3 GGACHVPEY-IGTPISFC 1748.8 
Peptide 6   
1 FVGRGTPIS 932.2 
2 CGAGFHVPCY 1052.1 
3 FVGRGTPISF and FVGRGTPISFY 1079.2 and 1242.6 
4 CGAGFHVPCYFVGRGTPIS, 
CGAGFHVPCYFVGRGTPISF, and 
CGAGFHVPCYFVGRGTPISFY 
1966.9, 2112.9 and 2276.0 
 
Figure 4.  RP-HPLC chromatograms of peptides 1 (top), 6 (middle) and MccJ25 (bottom) after 
incubation with pepsin at time 0 and 30 min. On the right side are shown the cleavage sites for 
the peptides.  A linear gradient was run on a C18 Vydac column (4.6 mm x 250 mm) over 35 
min from 15 to 50% isopropyl alcohol/water 0.05% (v/v) TFA with a flow rate of 2 mL/min. 
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MccJ25 displays antibacterial activity by inhibiting the RNA polymerase (RNAP) and/or 
the respiratory chain in the target organism, depending on the bacterial species.23,,19, 29,30 For 
Salmonella species MccJ25 targets both the RNAP and the cell respiration, however, for E. coli 
the target is mainly RNAP.  Peptides 1 and 6 most likely do not inhibit RNAP as they are 
inactive against E. coli as well as the lasso structure essential for RNAP inhibition is absent in 
these peptides. Different structure activity relationship studies of MccJ25 showed that lasso 
conformation (tail locked in ring) is important in RNAP interaction and inhibition.19,17  
Thermolysin-cleaved MccJ25 and MccJ25 lacking amino acids 13 to 17 inhibit RNAP 
transcription suggesting that the unusual lasso ring-tail part of the MccJ25 molecule interacts 
with RNAP, and blocks the secondary channel of the enzyme.17  Whereas, amidation of the C-
terminal glycine threaded through the MccJ25 lariat ring specifically blocks the RNAP 
inhibition.  The amidated MccJ25 peptide inhibits cell respiration.19 
To assess the effect of peptides 1 and 6 on the inhibition of cell respiration, the oxygen 
consumption of Salmonella newport in the presence of MccJ25, 1 or 6 was assayed.   Peptide 1 
inhibited oxygen consumption, whereas, peptide 6 had no effect on oxygen consumption (Figure 
5).  The findings from this experiment suggest that peptide 1 inhibits cell respiration in a manner 
analogous to MccJ25, and peptide 6 that did not inhibit cell respiration has an alternative 
mechanism of action.  Peptide 1, which lacks the lasso structure, seems to act primarily by 
inhibition of cell respiration which may also account for its decreased antimicrobial activity 
compared to MccJ25. 
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Figure 5.  Effects of treatment with MccJ25, peptide 1 and peptide 6 on the oxygen 
consumption.  Oxygen consumption of bacteria growing in the presence of peptides was 
expressed as a percentage of the oxygen concentration of the control culture (without peptides).  
Data correspond to mean values of three independent experiments.  Error bars correspond to the 
standard deviations. 
 
Finally, the cellular toxicity of MccJ25 and peptides 1-6 was investigated as a lead 
antibiotic must display low toxicity to mammalian cells.  The cytotoxicity of the peptides was 
evaluated using cell viability MTT assay against two cancer cell lines, MDA-MB-435 and MCF-
7 cells (Figure S3).  MccJ25 and the peptide derivatives displayed very low cytotoxicity (>80% 
cell viability) up to the highest concentration tested (100 µM).  Under similar conditions, a 
known antitumor agent doxorubicin showed only 20% cell viability at low concentration (3 M). 
Peptides 3-4 with charged residues or involving electrostatic interactions displayed slightly 
higher cytotoxic effect (75% cell viability) compared to the other peptides (> 90% cell viability).  
In general, the toxicity values observed were not significant when compared to the known 
antitumor agents.  In this context, it is of particular interest to note that Lopez et al. observed low 
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hemolytic activity for MccJ25 against red blood cells.24  Although MccJ25 displays antiapoptotic 
properties with isolated mitochondria,31 the low cytotoxicity could be due to its inability to 
permeate human cells. 
To summarize, two active peptides (1 and 6) derived from the sequence of MccJ25 are 
reported.  The design strategy used for obtaining active synthetic sequences from the MccJ25 
sequence suggests that (i) the folding of the C-terminal tail (in order to constraint the C-terminal 
tail near the lactam ring) can be achieved with a covalent disulfide bond formation (peptide 1) 
and (ii) the lactam (or lariat) ring can be substituted with a ring formed by a disulfide bond, 
however, it may require ring expansion (peptide 6).  The CD and resistance to proteases 
experiments suggest that the active peptides (1 and 6) do not fold into a lasso conformation, and 
peptide 1 displays antimicrobial activity by inhibition of target cell respiration.  Finally, the 
synthetic peptide derivatives of MccJ25 display minimal toxicity to mammalian cells and act 
specifically on bacterial cells. 
 
3. Experimental Section 
3.1 Reagents and Equipment 
Wang resin (0.58 mmol/g),  N-α-Fmoc-amino acids,  benzotriazol-L-yl-oxy-tris-
(dimethylamino)-phosphonium hexafluorophosphate (BOP), and (1-hydroxybenzotriazole) 
HOBt were purchased from NovaBiochem (San Diego, CA).  The side chains of amino acids 
were protected as follows: tert-butyl (tBu) for serine, threonine, tyrosine, tert-butyl ester (OtBu) 
or allyl ester (OAll) for glutamic acid, tert-butoxycarbonyl (Boc) for lysine, trityl (trt) for 
cysteine and histidine.  2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium 
hexafluorophosphate methanaminium (HATU), 5, 5’-dithiobis-2-nitrobenzoic acid (Ellman’s 
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reagent), N-methyl morpholine (NMM), triisopropylsilane (TIS), diisopropylethylamine 
(DIPEA) and trifluoroacetic acid (TFA) were purchased from Aldrich, while piperidine was 
purchased from Caledon (Canada). All other reagents were purchased from Sigma-Aldrich.  All 
commercial reagents and solvents were analytical grade and were used as received. 
RP-HPLC purification and analysis were carried out on a Varian Prostar (210 USA) 
HPLC system using Vydac semi-preparative C18 (1 x 25 cm, 5 μm), analytical C8 (0.46 x 25 
cm, 5 µm) and Agilent preparative C18 (21.2 x 25 cm, 7 μm) columns.  Compounds were 
detected by UV absorption at 220 nm.  Mass spectra were recorded on a MALDI Voyager time-
of-flight (TOF) spectrometer (VoyagerTM Elite) or on a Waters micromass ZQ.  Absorbance of 
the purple formazan product observed during MTT assay was measured using VERSA max 
microplate reader (Molecular Devices, Sunnyvale, CA, USA). All the procedures regarding the 
cell culture maintenance and treatment of cells were carried out in a level II biosafety cabinet.  
 
3.2 Peptide Synthesis and Purification 
3.2.1. General procedure 
Stepwise synthesis of peptides 1-6 was done manually on a 0.2-mmol scale of Wang 
resin (1.0% DVB cross-linked), following the standard Fmoc solid-phase peptide chemistry as 
described previously.32 Attachment of the first amino acid (5 equivalent) was carried out using 2, 
6 dichlorobenzoylchloride (DCB) in DMF/pyridine mixture. Successive couplings were 
performed by dissolving an excess (2 equiv) of Fmoc-protected amino acid and Castro reagent 
(BOP) in presence of (HOBt) to prevent racemization in DMF.  Coupling efficiency was 
monitored using the ninhydrin (Kaiser) test.33 The coupling step was repeated (double coupling) 
if Kaiser test was found positive.  In addition, a test cleavage was performed after each five 
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residues were coupled, and the desired product was confirmed by MALDI-TOF mass 
spectrometry.  Each peptide was cleaved from the resin using a mixture of 95% TFA, 5% 
triisopropylsilane, 5% water, for 120 minutes at room temperature with mechanical shaking. The 
filtrate from the cleavage reactions was collected, combined with TFA washes (3 x 2 min, 1 mL), 
and concentrated in vacuum. Cold diethyl ether (~ 15 mL) was added to precipitate the crude 
cleaved peptide. After triturating for 2 min, the peptide was collected upon centrifugation and 
decantation of the ether. The peptides were then purified using RP-HPLC. 
3.2.2. On resin amide cyclization (Peptides 1 and 2) 
For peptides 1 and 2, side chain of Glu was protected as allyl ester (OAll).  After 
complete assembly of the protected peptide on the resin, the side chain protecting group (allyl) of 
Glu8 (peptide 1) or Glu18 (peptide 2) was first removed.  Deprotection of the allyl from carboxyl 
group was carried out with Pd(PPh3)4 (0.08 equiv) and PhSiH3 (8 equiv) in DCM/DMF (45 mins 
x 3) under nitrogen.  The N-terminus Fmoc group was removed using 20% piperidine/DMF.  
The desired lactam linkage was then formed using HATU/DIPEA (2 equivalent) as the activating 
agents for 3 hours in DMF, after which complete cyclization was achieved. It was confirmed 
using ninhydrin test and MALDI-TOF. 
3.2.3. Oxidative folding and disulfide bond formation 
The purified linear (analogues 3-6) or lactam cyclized peptides (1-2) were dissolved in 50 
mM Tris buffer (pH 8.3) to a final concentration of 0.1 mM.  The peptide solution was then 
treated with 20% DMSO to assist in oxidation and enhance peptide solubility.  The reaction 
mixture was left stirring overnight at room temperature in an open flask. The oxidation was 
monitored using Ellman test,34 and MALDI-TOF mass analysis. The oxidation was complete in 
48 h.  A mass spectrum with M-2 indicated loss of two protons and formation of the oxidized 
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peptide. 
3.2.4. Peptide purification 
Purification of the peptides was done in two stages.  First, the crude linear or lactam 
cyclized peptides were reconstituted in 30-50% aqueous acetonitrile and purified on a semi-
preparative Vydac C18 reversed-phase (RP) HPLC column (10 x 250 mm, 5 μm, flow rate = 2 
mL/min, monitored at 220 nm) using different linear gradients of acetonitrile/water or isopropyl 
alcohol/water (0.05% TFA, v/v) mixtures.  The peptides were oxidized to form the disulfide 
bond, and were subjected to another RP-HPLC purification using preparative C18 HPLC column 
(21.2 x 250 mm, 7 µm).  This purification was essentially done to remove the salts from the 
reaction mixture.  The collected fractions were evaporated on the rotary evaporator followed by 
lyophilization to obtain the pure peptide.  The identity and purity of the peptides were assessed 
by analytical HPLC (Figure S1) and MALDI-TOF mass spectrometry (Figure S2).  The details 
of the purification methods and the elution time of each peptide are listed in Table S1.  In 
general, pure peptides were obtained with an overall yield of 7-32% and purity greater than 95%. 
 
3.3 Microcin J25 Expression and Purification 
The expression and purification of native MccJ25 were performed as described 
previously with some modifications.12  Briefly, the high copy number plasmid pTUC202 (a gift 
from Rutgers University, USA) which carries the MccJ25 biosynthetic gene cluster was 
transformed to competent E. coli MC4100 cells.  The cells were grown in M9 minimal media (2 
L) for 24 h at 37 C.  The culture supernatant was obtained by centrifugation at 4000 g for 15 
min, and then subjected to three successive purification steps. First, the supernatant was applied 
to flex column filled with XAD16 resin (Aldrich, CA).  Followed by elution in two successive 
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steps with 30:70 (v/v) and 80:20 (v/v) methanol/water mixtures.  Antibacterial assay was used to 
follow the peptide.  MccJ25 found in 80:20 (v/v) methanol/water fraction was next applied to 
C18 Megabond column (Varian, USA).  Three successive elution steps were carried out with 
40:60 (v/v), 60:40 (v/v) and 80:20 (v/v) methanol/water mixtures.  The 80:20 (v/v) fraction was 
further purified using C18 RP-HPLC (2 mL/min flow rate and absorbance monitored at 220 nm) 
under linear gradient from 55-80% methanol/water (0.05% TFA) in 45 min.  The concentration 
of the peptide was determined spectrophotometrically at 278 nm (molar absorptivity 3340 
M/L),18 and the yield was 2 mg. 
 
3.4 Antimicrobial Activity Assay 
The minimum inhibitory concentrations (MICs) of peptides 1, 6 and MccJ25 were 
determined by liquid growth inhibition assays in sterile 96–well plate using LB as growth 
media.22  Peptide stock solutions were prepared in 20% methanol/water (1 mM for MccJ55 and 
2.5 mM for 1 and 6), and were serially double diluted in sterile water to give concentrations 
ranging from 0.01 to 100 μM for MccJ25, and 0.5 to 250 μM for 1 and 6.  Similar concentration 
of methanol/water alone without the peptide did not change the growth of bacteria.  Bacterial 
culture (180 μL) diluted in LB media were added to the microplate wells to obtain optical density 
(OD620) of 0.02-0.05, followed by addition of peptide solutions (20 μL).  Each peptide 
concentration was tested in triplicate. Control wells contained the peptide in LB media as well as 
untreated bacterial cells. After incubation of the microplates for 24 h at 37 οC, the turbidity (OD) 
was read at 620 nm on a plate reader. MICs were defined from a growth curve as the lowest 
peptide concentrations that caused 100% growth inhibition (0.05 AU).  Three representative 
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growth curves of microcin J25, peptide 1, and peptide 6 obtained using broth assay against 
Salmonella newport are shown in Figure S4.  Standard deviations derived from MIC outcome of 
three graphs for three repeated experiments were calculated.  Concentrations of peptides stocks 
solutions were determined by absorbance at 280 nm described previously.35  The minimum 
bactericidal concentration (MBC) was determined from wells showing complete inhibition.  An 
LB agar plate was seeded on the surface with 10 μL from each clear well and incubated (24 h, 
37°C).  The MBC was defined as the lowest concentration giving no growth on an LB plate 
afterwards. 
 
3.5 Circular Dichroism (CD) Spectroscopy 
The CD measurements for the peptides (MccJ25, 1 and 6) were made on an Olis CD 
spectrometer (Georgia, USA) at 25 C in a thermally controlled quartz cell over 190-260 nm.  
All samples were dissolved in 100% methanol with a final concentration of 200 µM.  The length 
of the cuvette was 0.02 cm and number of scans was set to 10.  Smoothing and correction of the 
background spectra was performed afterwards.  The CD data was normalized and expressed in 
terms of mean residue ellipticity (deg cm2 dmol-1).  CD spectra were analyzed using quantitative 
curve fitting using the CDPro software analysis program as described previously.36 
 
3.6 Proteolytic Stability 
The enzymatic stability of peptides 1 and 6 compared to native MccJ25 was evaluated 
against two digestive enzymes (pepsin and chymotrypsin).  The susceptibility of 1 and 6 for 
chymotrypsin cleavage was assessed using spot on lawn method as reported previously.13  
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Peptide analogues 1 and 6 (10 L of 200 M) were spotted onto LB plates and chymotrypsin 
solution (10 µL of 0.5 mg/mL) was placed 1 cm away from the peptide spots. After the drops 
had dried, the plates were overlaid with 4 mL of soft agar inoculated with 107 cells of a clinical 
isolate of Salmonella enterica serovar Newport. After overnight incubation at 37 °C, the growth 
inhibition zones around the drops were recorded. MccJ25 was used as control at 5 M 
concentration. 
Pepsin was dissolved in 0.1 N HCl (4% w/w) and then peptide 1 or 6 was added (150 
M).37 The solution was incubated at 37 °C and the degradation was stopped at specific time 
points 0 min, 30 min, 1 hr, by taking 100 μL aliquots into 10 μL 0.1 N NaOH containing 70% 
methanol to precipitate the enzyme.  Sample was centrifuged at 16000 g for 10 min, and the 
supernatant containing the cleavage mixture was injected in RP-HPLC.  Fractions were collected 
for mass detection using MALDI-TOF to determine the labile sites. Also fragments were 
analyzed for antibacterial activity using spot on Lawn as described earlier.  For sake of 
comparison the same experiment was repeated for native MccJ25. 
 
3.7 Oxygen Consumption Determination 
Oxygen consumption was determined as previously described.38  Salmonella newport 
strain were grown to exponential phase (OD600 0.4-0.5) in LB media.  Samples were diluted in 
LB media to an OD600 of 0.2.  Cells were then incubated at 37 °C with either MccJ25 (0.25 μM), 
1 (25 μM), or 6 (30 μM) for 35 min.  Thereafter, the average rate of respiration for subsequent 5 
min was polographically measured with a 2 mL Gilson Clarke electrode oxygraph at 37 °C.  A 
control experiment in the absence of peptide was carried out similarly. 
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3.8 Cell Viability Assay 
3.8.1 Cell lines 
Tumor cell lines used in this study included MDA-MB-435 and MCF7 breast cancer cell 
lines.  MDA-MB-435 cells were cultured in RPMI 1640 medium (Sigma) supplemented with 
FBS (10%), penicillin (50 µg/mL), and streptomycin (0.05 g/mL) in a humidified atmosphere 
(5% CO2) at 37 C.  MCF7 cells were grown in DMEM media supplemented with same 
additives as stated above. 
3.8.2 MTT cytotoxicity assay 
The cellular toxicity of MccJ25 and the peptide derivatives was determined by measuring 
the cell growth inhibition using MTT assay.39 Two cancer cell lines were used, MDA-MB-435 
and MCF7 cells.  Cells were seeded in 96 well plates (Corning Inc., MA, USA) at a 
concentration of 1 x 104 cells/well (100 µL) in complete media and were incubated at 37 C in 
5% CO2 atmosphere.  After 24 hours, the cells were treated with aseptic samples.  Samples (1 
mM, MccJ25 and peptides) were prepared in sterile 10% DMSO/water followed by filtration 
through 0.2 μM filter.  The cell culture media were added to the 96 well plate (180 μL/well) 
followed by addition of peptide sample solution (20 μL/well), serially double diluted to give 
concentrations ranging from 0.3125 to 100 μM.  Doxorubicin was used as a positive control and 
untreated cells were used as a negative control.  The plates were incubated for another 24 hours 
following which the culture media was aspirated and replaced with 100 μL MTT solution (5 
mg/mL in media).  The cells were incubated for 3.5 hours to allow interaction with MTT 
solution.  Following incubation, the media was removed by vacuum, and the purple formazan 
product precipitated in each well was solubilized in DMSO (100 μL), and the absorbance was 
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measured at 570 nm using microtitre reader.  The percentage cell viability was expressed as the 
absorbance ratio of cells treated with peptides to untreated cells dissolved in complete media.  
All experiments were done in triplicate, and the data is presented in the form of mean. 
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